Latest News and Press Releases
Want to stay updated on the latest news?
-
AIV001 is currently in development for evaluation in Superficial and Nodular Superficial Basal Cell Carcinoma (sBCC and nBCC) COSA MESA, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) -- AiViva Biopharma...
-
Novel JEL™ Technology for Periocular Administration COSTA MESA, Calif., Aug. 23, 2024 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company, announced that it has fully...
-
Novel Non-surgical Intradermal Treatment for Basel Cell Carcinoma COSA MESA, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company, announced...
-
COSTA MESA, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company developing innovative therapies to address major unmet medical needs, today...
-
加利福尼亞州科斯塔梅薩, Aug. 29, 2023 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc. 是一家臨床階段生物技術公司,致力於開發創新療法以應對潛力巨大的醫療需求,其於今日宣布任命 Jung-Chin (Rongjin) Lin 先生為其董事會成員。Jung-Chin (Rongjin) Lin 先生是 Center Laboratories,...
-
COSTA MESA, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company developing innovative therapies to address major unmet medical needs, today...
-
Novel JEL™ Technology for Periocular Administration COSTA MESA, Calif., May 22, 2023 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company, announced that it has begun a...
-
NEWPORT BEACH, Calif., Oct. 02, 2020 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company, announced that it has begun dosing patients diagnosed with superficial or...
-
AIV001 was shown to be safe and well tolerated after local intradermal treatment of incisional wounds Reduction in fibrosis was observed from single AIV001 treatment post-wounding NEWPORT BEACH,...